In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterol-mediated gene transfection

Torben Gjetting1
Nicolai Skovbjerg Arildsen1
Camilla Laulund Christensen1
Thomas Tuxen Poulsen1
Jack A Roth3
Vagn Neerup Handlos2
Hans Skovgaard Poulsen1

1Department of Radiation Biology, Finsen Center, RH Pharmacy, Copenhagen University Hospital, Copenhagen, Denmark; 2Thoracic Medical Oncology, MD Anderson Cancer Centre, Houston, TX, USA

Background: DOTAP/cholesterol-based lipoplexes are successfully used for delivery of plasmid DNA in vivo especially to the lungs, although low systemic stability and circulation have been reported. To achieve the aim of discovering the best method for systemic delivery of DNA to disseminated tumors we evaluated the potential of formulating DOTAP/cholesterol lipoplexes with a polyethylene glycol (PEG)-modified lipid, giving the benefit of the shielding and stabilizing properties of PEG in the bloodstream.

Method: A direct comparison of properties in vitro and in vivo of 4 different DOTAP/cholesterol-based lipoplexes containing 0%, 2%, 4%, and 10% PEG was performed using reporter gene activity and radioactive tracer lipid markers to monitor biodistribution.

Results: We found that 10% PEGylation of lipoplexes caused reduced retention in lung and heart tissues of nude mice compared to nonPEGylated lipoplexes, however no significant delivery to xenograft flank tumors was observed. Although PEGylated and nonPEGylated lipoplexes were delivered to cells the ability to mediate successful transfection is hampered upon PEGylation, presumably due to a changed uptake mechanism and intracellular processing.

Conclusion: The eminent in vivo transfection potency of DOTAP/cholesterol-based lipoplexes is well established for expression in lung tumors, but it is unsuitable for expression in non first pass organs such as xenograft flank tumors in mice even after addition of a PEG-lipid in the formulation.

Keywords: gene delivery, DOTAP, polyethylene glycol (PEG), biodistribution, lung cancer, xenograft tumor model

Efficient gene delivery in vivo based on nonviral methods remains a major challenge in the field of gene therapy, where an overwhelming variety of polymeric and liposomal compounds have been tested.1 A major obstacle has been the fact that extremely efficient methods involving cationic liposomes for gene delivery to cells in vitro perform very poorly when tested in animals.2 Although a regime of transfection-potent lipoplexes has been established in vitro,3,4 presumably in vivo applications require different physical and chemical properties and limited information about the performance for in vivo delivery has emerged.

A notable exception is 1,2-dioleoyl-3-trimethylammonium-propane/cholesterol (DOTAP/chol)-based lipoplexes, that are potent in cellular transfection and importantly facilitate systemic delivery of DNA to cells in vivo.5–8 DOTAP/chol complexed to plasmid DNA encoding the tumor suppressor gene FUS1 has been used successfully for the treatment of xenograft tumor model of non-small cell lung carcinoma (NSCLC)9 and is currently being exploited in a clinical setting for the treatment of NSCLC.
patients. When these lipoplexes are administered to end-stage NSCLC patients a positive response has been reported.\textsuperscript{10}

DOTAP/chol-based lipoplexes show attractive properties: i) Easy formulation in that preformed liposomes are simply mixed with plasmid DNA and spontaneously organize into multilaminary vesicles\textsuperscript{11} and ii) the preparation of these particles for clinical use has been refined and is FDA approved.\textsuperscript{12} However suboptimal properties relating to systemic stability have been reported when tested in comparison to other formulations.\textsuperscript{2,13}

To develop a strategy involving transcriptionally targeted suicide gene therapy of small cell lung carcinoma (SCLC),\textsuperscript{14–16} which at the time of diagnosis often appear disseminated to various extrathoracic organs,\textsuperscript{17} a systemic distribution of the therapeutic agent is demanded. It remains to be determined if DOTAP/chol is an optimal choice for this malignancy or whether improvements must be made for systemic stability and circulation.

Liposome modification by a shielding poly-ethylene-glycol (PEG) component in the formulation has been reported to enhance the systemic stability greatly.\textsuperscript{18–22} Furthermore the biophysical relationship between liposome surface concentration and structure of PEG has been characterized in detail.\textsuperscript{23,24} Recent reports about the delivery of plasmid and siRNA using cationic lipoplexes that also contain a PEG-lipid for improved efficiency\textsuperscript{19,25,26} prompted us to assess the usability of different degrees of PEGylation of DOTAP/chol/plasmid DNA lipoplexes in relation to improved systemic circulation and stability while maintaining the favorable transfection properties.

Hence, in the present study we aimed to evaluate the effect of increasing PEGylation of DOTAP/chol lipoplex-mediated gene delivery in the form of plasmid DNA and characterize the biophysical properties in relation to systemic stability, biodistribution, and uptake mechanism. Using enhanced green fluorescence protein (EGFP) and firefly luciferase (LUC) reporter genes, endocytosis inhibitors, and labeled lipids we investigate the potential use for systemic tumor delivery and assess the barriers operating at the level of intracellular uptake.

**Material and methods**

**Materials**

All chemicals eg, synthetic cholesterol were purchased from Sigma-Aldrich Inc. (Brøndby, Denmark) unless otherwise stated. DOTAP (N-[1-(2,3-dioleyl)propyl]-N,N,N-trimethylammonium chloride), DSPE-PEG\textsubscript{2000} (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)]-2000) and 25-NBD-cholesterol (25-[N-[(7-nitro-2-1,3-benzoxadiazol-4-yl)methyl] amino]-27-norcholesterol) were purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA). [1,2-\textsuperscript{3}H]-Cholesteryl Hexadecyl Ether (‘H-CHE) was purchased from Perkin Elmer (Skovlunde, Denmark). High quality plasmids: pCMV-LUC (sequence available upon request) and pEGFP-N1 (Clontech, Mountain View, CA, USA) preparations were made with the endo-free Giga kit from Qiagen GmbH (Hilden, Germany) according to the manufacturer’s instructions. Glassware used for lipid work was washed and rinsed in milliQ water, baked at 180°C for 6 hours and dust was removed using pressurized air. Lipid solutions in chloroform were handled with gastight glass syringes (Hamilton, VWR, Herlev, Denmark) reserved for this purpose. Syringes were rinsed with chloroform and 20% ethanol in water only.

The H1299 and NCI-H69 cell lines (obtained from ATCC, Boras, Sweden) were cultivated in RPMI medium supplemented with pen-strep and 10% fetal calf serum (Invitrogen Inc., Taastrup, Denmark). Six week old male NMRI mice were bought from Taconic Europe (Lille Skensved, Denmark) and housed at Department of Experimental Medicine, University of Copenhagen. All animal experiments were performed according to ethical guidelines and under valid license from the Danish Animal Experimentation Board.

**Method**

**Preparation of DOTAP/cholesterol/DSPE-PEG\textsubscript{2000} liposomes**

The protocol described by Ramesh\textsuperscript{7} for preparation of DOTAP/chol liposomes at the 300 µmol scale was followed with minor modifications. Briefly, equimolar amounts (150 µmol each) of the lipids were dissolved and mixed in chloroform and placed in a rota-vaporator (BÜCHI Labortechnik AG, Flawil, Switzerland) in a 1 L round glass bottle. The solvent was evaporated under a nitrogen gas stream and the lipid film was dried by high-vacuum for several hours. Hydration was done by adding 7 mL glucose (5%) solution resulting in a 40 mM total lipid concentration and placed at 50°C for 30 minutes with repeated rotary movement to ensure complete hydration of the lipids and left overnight at room temperature. The next day the liposome preparation was placed in a metal basket and sonicated for 5 minutes at 50°C using a Bransonic water bath (MT-1510, 42 kHz, 80 W, setting “sonics”, Branson Ultrasonics, Danbury, CT, USA) and then downsized using 11 passes in a small-scale extruder (Avanti Polar) with polycarbonate nanopore filters (400 nm, 200 nm, and 100 nm, Whatman, Frisenette, Knebel, Denmark) at 50°C. This reagent was designated A-0.
For investigations about the effect of PEGylation, liposomes were prepared at a smaller scale (20 μm). Chloroform solutions of DOTAP, cholesterol, and eventually DSPE-PEG2000 and tracer-lipids were mixed in a glass tube (12 × 75 mm) according to the scheme in Table 1. While vortexing the solvent was evaporated under a thin nitrogen gas stream. High-vacuum drying of the lipid film was followed by hydration in 0.47 mL glucose (5%) resulting in a 40 mM total lipid solution. The tubes were sealed and placed at 50°C for 30 minutes with repeated rotary movement to ensure complete hydration of the lipids and left overnight at room temperature. The next day the liposome preparations were sonicated for 2 minutes at 50°C and then downsized using a small-scale extruder (Avanti Polar) as above. Sonication for 5 minutes with this preparation caused clearing of the solution indicative of disrupted liposomes, hence the time was reduced to 2 minutes. MALDI-TOF mass spectrometry analysis of the liposome preparation made at 20 and 300 μm scales respectively did not reveal any differences in the composition (TL Andresen, personal communication).

DNA/lipoplex formation, in vitro, and in vivo transfection
Adherent H1299 were plated the day prior to the experiment in 6-well plates, with 300,000 cells per well. NCI-H69 cells growing in suspension were single-cell resuspended on the day of the experiment and counted in a hemocytometer using Trypan Blue (0.4%) staining to discriminate from dead cells before placing 2 × 10^6 cells in 6 well plates. If the effect of endocytosis inhibitors was found in the experiment, the cells were incubated with inhibitors for one hour prior to lipoplex addition. Initially, the cytotoxicity of endocytosis inhibitors: chloroquine (inhibiting acidification of endosomes and lysosome fusion), chlorpromazine (inhibiting clathrin-mediated endocytosis), filipin (inhibiting caveolae-mediated endocytosis), and cytochalasin B (inhibiting macropinocytosis) was determined in NCI-H69 and H1299 cells in the range reported previously by others. Concentrations causing approximately 30% decrease in MTT cell viability were selected (data not shown, see legend of Figure 6). Twenty microlitres (0.8 μm) of liposome preparations with varying amounts of PEG-lipid were diluted and mixed by rapid pipetting up and down with DNA solutions containing pEGFP-N1 and pCMV-LUC (22.5 μg each) yielding a total volume of 100 μL DNA/lipoplex solution. For in vitro studies, after 30 minutes at RT the DNA/lipoplex (2.5 μg/40 mmol) was added to cells in full growth medium and incubated for 2 days at 37°C before analysis of reporter activity. For in vivo applications the mixing was done with maximally 300 μL of total volume, and batches were pooled if larger amounts were required. Intravenous injection of 100 μL was administered within 2 hours of mixing.

Gene expression analysis
Adherent cells were trypsinized and suspension cells were single-cell resuspended and transferred to Eppendorf tubes in two aliquots and washed with phosphate-buffered saline (PBS). One aliquot was analyzed by flow cytometry using a FACS Canto II instrument (BD Biosciences, Franklin Lakes, NJ, USA) gating EGFP-positive cells using the blue laser (488 nm) and detecting fluorescence light in each cell at 538 ± 10 nm. A nontransfected control cell sample was used to adjust for autofluorescence. The second cell aliquot of each sample was pelleted and lysed in 10 μL passive lysis buffer (Promega Inc., Madison, WI, USA) for 10 minutes. After centrifugation for 1 minute, the supernatant was analyzed for luciferase activity (20 μL; Luciferase kit, Promega) using a luminometer (Lumat LB9507; Berthold, Bad Wildbad, Germany) and total protein concentration (20 μL, 10 times diluted, BCA kit, Pierce/Thermo, Rockford, IL, USA) using an OpsysMR microplate reader (Dynex Technologies GmbH, Berlin, Germany). Using a purified, recombinant firefly luciferase (Promega) for standardization, luciferase activity was expressed as picogram luciferase enzyme per milligram of total protein (pg luc/mg protein). When fluorescing lipid was incorporated in the lipoplex, the cell lysates of transfected cell samples were analyzed in a microplate fluorometer (Ex. 485 ± 10 nm, Em. 530 ± 10 nm, Synergy 2, Biotek Instruments Inc., Winooski, VT, USA).

Particle characterization
DNA/lipoplexes were analyzed by agarose gel (1%) electrophoresis followed by ethidium bromide staining to

---

**Table 1 Liposome components**

| Name | Lipid components (mol%) |
|------|-------------------------|
|      | DOTAP | Chol | DSPE-PEG2k | 25-NBD-chol | H-CHE |
| A-0  | 50    | 50 (48.5) | 0 | (1.5) | 0.0025 |
| B-2  | 50    | 48 (46.5) | 2 | (1.5) | 0.0025 |
| C-4  | 50    | 46 (44.5) | 4 | (1.5) | 0.0025 |
| D-10 | 50    | 40 (38.5) | 10 | (1.5) | 0.0025 |

**Notes:** The names of the formulations used in the study reflect the percentage of PEG-lipid. When fluorescent cholesterol was included, 1.5 mol% 25-NBD-cholesterol was added and the unlabeled cholesterol was reduced accordingly (shown in parentheses). For assessment of biodistribution in vivo H-CHE was included (0.0025 mol%, 50 Ci/mmol). **Abbreviations:** DOTAP/chol, 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt)/cholesterol; PEG, polyethylene glycol; NBD, 7-nitro-2,1,3-benzoxadiazol; SCLC, small cell lung carcinoma; NSCLC, non-small cell lung carcinoma; i.v., intravenous; PDI, polydispersity index.
visualize bound and free plasmid DNA. A Zetasizer Nano ZS (Malvern Instruments Inc., Malvern, UK) was used for characterizing the particle size by dynamic light scattering and zeta potential. Preparations of liposomes and DNA/lipoplexes were diluted to approximately 1 mM total lipid and placed in a clear disposable zeta cell (Malvern). First, size was determined using four cycles of 3 minutes at standard settings for vesicles and with general purpose parameter settings. The quality of size measurements given as the volume-weighted mean diameter were analyzed by evaluating polydispersity index (PDI), scattering correlation, and cumulants fit. Subsequently samples were analyzed for zeta potential of particles using standard settings with three repeated measurements of >20 zeta runs and assessing the quality of measurements by evaluation of the phase plot.

SCLC tumor model establishment
The SCLC xenograft model was established by the injection of 5 × 106 NCI-H69 cells per flank subcutaneously into 6–8-week-old male nude NMRI mice. Tumors from injected mice (termed passage 0) were used for serial transplantation of mice that entered experimental protocols (passage 1) or used for serial transplantation of new animals (passage 2). Xenograft tumors used in the experiments were passaged up to four times. Untreated tumors from each passage were subjected to pathological analysis to evaluate the existence of clinically validated SCLC markers.

Luciferase activity, pharmacokinetics, biodistribution in vivo
Male NMRI nude mice were injected in the lateral tail vein with 100 µL lipoplex prepared as described above. Unlabeled lipoplex without PEG-lipid (A-0*) was administered once for serial transplantation of mice that entered experimental protocols (passage 0) or used for serial transplantation of new animals (passage 2). Xenograft tumors used in the experiments were passaged up to four times. Untreated tumors from each passage were subjected to pathological analysis to evaluate the existence of clinically validated SCLC markers.

Using the lipid marker ³H-CHE, tritium-labeled DNA/lipoplexes with varying degrees of PEGylation were injected in a single dose (100 µL) containing approximately 1 µCi tritium label. In these experiments half of the homogenate (500 µL) was isolated for scintillation counting before centrifugation. If more than 90% of the counts were found in the tail sample the injection was considered as failed and the mouse was excluded from the experiment. Blood samples (100 µL) were drawn from the eye by periobital plexus puncture after 15 minutes, 2 hours, 5 hours, and 24 hours, and immediately mixed with 10 mL scintillation liquid (UltimaGold, Perkin Elmer, Skovlunde, Denmark) and counted in a Beckman LS 6500 liquid scintillation counter (Beckman Instruments, Fullerton, CA, USA). After the last blood sampling the animals were euthanized and organs sampled and analyzed as above. Due to the low systemic distribution of radiolabel no blood correction factor was applied to organ values.

Results
Gene expression analysis in vivo
The DOTAP/chol/DNA lipoplex has previously been shown to facilitate gene expression in primarily lung and heart tissue when administered intravenously by tail vein injection to NSCLC models in nude mice. We inoculated NCI-H69 cells subcutaneously (s.c.) on the flanks of NMRI nude mice for testing of the ability of the DOTAP/chol lipoplexes to facilitate gene expression in SCLC s.c. xenografts. The tumors reached approximately 200–500 mm³ in size when the experiment was started. Lipoplexes were prepared with DOTAP/chol (formulation A-0’) and pCMV-LUC plasmid and three daily tail vein injections of xenografted nude mice were performed. The animals were sacrificed on the fourth day and selected organs were sampled and luciferase activity was assayed in protein extracts (Figure 1). We detected luciferase expression in lung and heart tissue, whereas the activity was three to four orders of magnitude.

Figure 1 Luciferase reporter gene expression in vivo. After three consecutive daily tail vein injections of DOTAP/chol/DNA lipoplex (A-0’) in nude mice organs were sampled on the fourth day and assayed for luciferase activity, n = 4. Assay background was at 10 pg luc/g protein (indicated with dotted line).
lower, below assay background (10 pg luc per g protein) in tumor, liver, kidney, and spleen tissue samples. We interpreted this finding as showing that DOTAP/chol lipoplexes have insufficient systemic stability to reach beyond first-pass organs and speculated that the required improvement in biodistribution might be obtained by adding a PEGylated lipid to the lipoplex formulation.

**Liposome particle and lipoplex characterization**

In order to investigate the usability of modifying the lipoplex with PEG-polymer, four formulations of 100 nm-extruded DOTAP/chol liposomes designated A-0, B-2, C-4, and D-10, containing 0%, 2%, 4%, or 10% DSPE-PEG2000 lipid respectively, were evaluated. Table 1 shows the composition of each formulation. Immediately after mixing the liposomes with plasmid DNA the solution became cloudy white indicating lipoplex formation, as observed by others. 

A small aliquot of lipoplex (0.2% of each preparation) was analyzed by agarose gel electrophoresis. In agreement with predicted molar excess of lipid, all DNA was complexed to lipoplex, since no DNA was observed migrating as free plasmid DNA (Figure 2).

The ratio of positively charged lipids to negatively charged DNA was calculated to be 2.6. Before and after mixing with DNA the size, polydispersity index (PDI), and charge were assessed using dynamic light scattering and zeta potential measurements (a typical experiment is described in Figure 3).

All four liposome preparations have particle sizes in the range 113 ± 0.5–130 ± 0.4 nm and low polydispersity indices (0.066 ± 0.012–0.149 ± 0.01). The zeta potential is gradually decreasing from +65.6 ± 0.74 mV in A-0 to +44.7 ± 3.47 mV in D-10 concurrent with increasing content of the negatively charged DSPE-PEG2000 lipid. The model of PEG-surface structure being mushroom-like at concentrations below 4%, whereas brush-like structures exist at higher PEG-lipid mol-percentages (eg, 10%). Interestingly, we found that upon mixing with DNA the size of lipoplexes increase and lipoplexes containing 2% or 4% PEG-lipid form micrometer scale aggregates, whereas the A-0 and D-10 lipoplex have sizes 784 ± 49 and 327 ± 5.3 nm, respectively. This finding is in accordance with PDI values that are close to 1 for A-0, B-2, and C-4 lipoplexes indicating high turbidity, whereas D-10 lipoplex has a medium PDI of 0.472. Upon mixing with

---

**Figure 2** Agarose gel electrophoresis/ethidium bromide staining of DNA/lipoplexes with different content of PEG-lipid compared to the migration of free plasmid DNA (free DNA) and a DNA size marker.

**Figure 3** Physical characterization of lipoparticles using a Zetasizer. Each of the four liposome formulations was analyzed before (white columns) and after (grey columns) mixing with plasmid DNA. A) The hydrodynamic size. B) The polydispersity index. C) The zeta potential of the particles. The estimate and the standard error are given for each measurement. Three independent experiments yielded equivalent results.
negatively charged DNA, the zeta potential of the particles is reduced accordingly, but the lipoplex particles/aggregates maintain a high positive charge (ranging from 47.8 ± 1.56 to 35.4 ± 1.58). The properties of lipoplexes described above were consistently found when lipids were prepared at the scale of 20 µmol in at least three independent experiments, however when preparing the DOTAP/chol particles according to the standard protocol at the scale of 300 µmol (designated A-0’ in Figure 3) the lipoplexes were measured to be below half a micrometer (492 ± 21 nm) in accordance with previously published results of lipoplexes used for translation investigations. Zeta-potential measurements were similar for lipoplexes arranged at both preparation scales (A-0 and A-0’).

Gene expression analysis in vitro

Equal amounts of pCMV-Luc and pEGFP-N1-expression plasmids encoding LUC and EGFP genes were mixed with A-0, B-2, C-4, or D-10 liposomes and used in transfection of two lung cancer cell lines H1299 or NCI-H69. Forty-eight hours later the cells were analyzed for reporter gene expression, either by measuring the percentage of EGFP-positive cells by flow cytometry (Figure 4a) or by measuring the overall amount of luciferase activity expressed in relation to total protein in cell lysates (Figure 4b).

With the presence of PEG-lipid in the lipoplex a dramatic decrease in the number of EGFP-positive cells from 47% ± 6.9% with A-0 to 3.6% ± 1.8% with B-2 in H1299 cells and from 30% ± 1.9% with A-0 to 2.6% ± 1.8% with B-2 in NCI-H69 cells. Transfections with lipoplexes C-4 or D-10 yielded even lower transfection efficiencies around 1% to 2% of the cells being successfully transfected (Figure 4a). In accordance with this, the luciferase activity is gradually decreasing roughly 10-fold in each step from 213 ± 89 ng luc/mg protein with A-0 to 145 ± 47 pg luc/mg protein with D-10 in H1299 cells and 11 ± 5.2 ng luc/mg protein with A-0 to 3.0 ± 1.2 pg luc/mg protein with D-10 in NCI-H69 when analyzing the cell samples transfected with lipoplexes A-0, B-2, C-4, and D-10, respectively (Figure 4b).

Kinetics of cellular uptake

In order to investigate the kinetics of cellular uptake of the lipoplexes the four formulations with increasing PEG-lipid were prepared with 1.5% 25-NBD-cholesterol, a green fluorescence lipid reporter that has previously been used to study liposome transport. Since the EGFP expression would overlap spectrally with the labeled cholesterol fluorescence, only LUC-expression plasmid was used for lipoplex formation. Essentially the same reporter activities were obtained as with the unlabeled lipoplexes (data not shown). Furthermore, microscopic and FACS flow cytometry analyses showed that for all four mol-percentages of PEG-lipid, virtually all cells (99%) contained the fluorescing cholesterol in similar subcellular compartments two days after transfection (Figure 5a) and this prompted us to measure the uptake kinetics on a shorter time scale.

Hence Figure 5b shows the cell lysate fluorescence of NBD-cholesterol at 1, 4, 24, and 48 hours after addition of labeled lipoplexes to H1299 cells. A remarkable difference in uptake kinetics is observed. The fluorescence in cells transfected with lipoplex without PEG-lipid (A-0) is unchanged from one hour after transfection to two days (ANOVA: P = 0.45: no change), whereas fluorescence in cells transfected with lipoplexes with 2%, 4%, or 10% PEG-lipid (B-2, C-4, or D-10) accumulates over time (ANOVA: P values < 0.002 in all three cases: significant change), reaching a maximum of fluorescence after 24 to 48 hours. Regression analysis confirms this difference (linear equation fits are shown in Figure 5 legend).
all of which have been described as being useful in relation to nonviral gene transfer. Luciferase reporter activity was evaluated in H1299 and NCI-H69 cells and most profound effects were observed in NCI-H69 cells (Figure 6a).

Here it was found that all lipoplexes were sensitive to cytochalasin B decreasing luciferase activity between 4- and 16-fold (2–2^1/2-fold) indicating that the uptake mechanism involves macropinocytosis or that actin filaments are involved in intracellular processing. Only the transfection with the largest particles made with DNA/C-4 lipoplexes was decreased two fold by filipin indicative of a caveola-based dependent uptake. With regards to chloroquine and chlorpromazine a large difference in sensitivity was observed between non-PEGylated and PEGylated lipoplexes. A-0-based lipoplexes yielded roughly 16-fold less reporter activity in the presence of these inhibitors, and in contrast hereto, PEGylated lipoplexes made with C-4 yielded four fold more reporter activity, and D-10-based lipoplexes facilitated 1.6-fold more luciferase activity in the presence of chloroquine. In adherent H1299 cells (Figure 6b), effects of inhibitors were less significant, although the same pattern of lipoplex sensitivity could be recognized from that of NCI-H69 cells. Chloroquine and chlorpromazine reduced luciferase activity 16- and 32-fold, respectively in case of A-0 lipoplex, whereas B-2 lipoplexes yielded 16-fold more activity when the cells were exposed to chlorpromazine. Although the exact action of inhibitors may be uncertain, taken together these data strongly suggest that the cellular uptake of naked and PEGylated lipoplexes depend on different mechanisms. All experiments were averaged from 3–5 independent experiments and at least two different preparations of liposomes.

Biodistribution and stability
Discrepancies between transfection in vitro and in vivo has been reported previously and the finding that PEGylated DOTAP/chol lipoplexes are taken up efficiently over time by cancer cells in vitro, albeit gene expression is hampered, prompted us to investigate the potential of the lipoplexes formulated with different mol.-percentage of PEG-lipid in vivo. The intracellular processing of lipoplexes is different in various organs and cell types, and the putative stabilizing effect of PEG-lipid in the formulation could influence the effectiveness in cellular transfection between the four formulations in vivo. Using the nonexchangeable and nonmetabolizable lipid marker 3H-CHE, lipoplexes were prepared and injected in the tail vein of tumor-bearing NMRI nude mice and blood was drawn by periobital plexus sampling 15 minutes, 2 hours, 5 hours, and 24 hours after injection of lipoplex.

Mechanism of cellular uptake, effect of endocytosis inhibitors
In order to investigate whether the changed transfectability of PEGylated lipoplexes could be due to an altered uptake mechanism cell culture transfections were done in the presence of four different drugs known to interfere with endocytosis, namely chloroquine that inhibits acidification of endosomes and lysosome fusion, chlorpromazine that inhibit clathrin-mediated endocytosis, filipin, a sterol binding compound that inhibit caveolae-mediated endocytosis and cytochalasin B that inhibit actin polymerization and macropinocytosis.

Figure 5 Cellular uptake of fluorescently labeled lipoplexes. A) Bright-field and fluorescence microscope pictures taken two days after H1299 cells were transfected with NBD-labeled A-0 (upper panel) and D-10 lipoplexes (lower panel). Scale bar marked in red indicates 15 µm. B) NBD fluorescence in cell lysates was measured at different time points after addition to cell cultures. Non-PEGylated A-0 lipoplex is rapidly taken up by cells to a saturating level within one hour and remain constant hereafter. Fitted lines: B-2: Fluorescence index ±(average are normalized and averaged from triplicates of three independent experiments ± (average ± (time). Slope confidence interval exclude 0. Data were normalized and averaged from triplicates of three independent experiments and at least two different preparations of liposomes.
The radioactive dose was 0.5 μCi corresponding to approximately $1.2 \times 10^7$ cpm (background 9 cpm). Interestingly, when 100 μL blood samples from animals were counted by scintillation, only small amounts of tritium were found, indicating a poor systemic spreading of the radioactive dose to the vein blood drawn from the eye. Figure 7a shows the tritium counts of isolated blood samples over time after background subtraction. Blood sampled 15 minutes after tail vein injection of lipoplexes with 0%, 2%, or 4% PEG-lipid contained tritium only 6 to 9 times over background, whereas samples drawn from animals injected with D-10 lipoplex contained approximately 18 times over background, however in all cases, only a very small fraction of the injected dose. Five hours after injection all blood samples contained the same low amount of radioactivity.

After 24 hours the animals were sacrificed and selected organs were sampled and assayed for luciferase activity and accumulation of tritium-tracer. Figure 7b shows the luciferase activity in tumor, heart, lung, liver, kidney, and spleen samples from animals injected with a single dose of lipoplex formulated with 0%, 2%, 4%, or 10% PEG-lipid. In general, only heart and lung tissue of animals receiving plasmid DNA in lipoplexes contain luciferase activity considerably above assay background, and this was gradually decreasing with increasing PEGylation. D-10 lipoplexes yielded more luciferase activity in the lung than C-4, however no activity in heart tissue could be measured. Additionally, the spleen sample from mice injected with A-0 lipoplex showed luciferase activity above background. Importantly, no luciferase activity was measured in tumor tissue from mice injected with lipoplex.

The relative distribution of radioactive lipid tracer in tumor, heart, lung, liver, kidney, and spleen tissues is shown in Figure 7c and there is a gradual change with high

---

**Figure 6** Effects of endocytosis inhibitors on luciferase reporter activity measured in (A) NCI-H69 and (B) 1299 cells. Cells were incubated one hour prior to transfection and then exposed to inhibitors for the entire incubation (48 hours). Chloroquine (20 μM (NCI-H69), 30 μM (H1299)), chlorpromazine 10 μM (NCI-H69), 20 μM (H1299), filipin (4 μM), and cytochalasin B (25 μM). Data from 3–5 independent experiments were pooled and log2 transformed to obtain fold change in expression. Error bars indicate standard error of the mean, * means that 0 is not included in confidence interval ($P < 0.05$), no change: N.S.
In vivo transfection with PEGylated lipoplex accumulation in the heart and lungs in case of lipoplex A-0, B-2, and C-4 to high liver accumulation of the lipoplex containing 10% PEG-lipid (D-10).

Discussion
Effect of PEGylation in vitro
Previous efforts in nonviral gene delivery using DOTAP/chol-based lipoplexes have proven successful in obtaining efficient cellular transfection in vitro and in vivo using xenograft subcutaneous flank tumors by intratumoral injection or orthotopic micrometastatic lung tumor model of NSCLC by intravenous injection. We recently reported the successful use of DOTAP/chol lipoplexes for delivery of suicide gene therapy by intratumoral injection. The rapid clearance from the system of intravenously injected DOTAP/chol-based lipoplexes have been reported, and since our gene therapy strategy is aimed at the systemic treatment of subcutaneous xenograft tumors and eventually disseminated SCLC, in this study we sought to stabilize and increase the circulation time of DOTAP/chol-based lipoplexes that have been modified with different amounts of PEG-lipid, ie, without abolishing the eminent ability to transfect cells. Several other works have reported the effect of PEGylation of lipoplexes made from DOTAP or other cationic lipid and with DOPE as the helper lipid, and we discuss these in relation to our findings with PEGylation of DOTAP/chol-based lipoplexes further below.

A remarkable threshold in physical properties appears to exist at 5% PEG-lipid in lipoplexes. PEG-lipid content of a few to 4% causes aggregation and micrometer-sized particles whereas 5% to 10% of PEGylated particles remain smaller. We applied the lipoplex conditions of Ramesh which utilize a P/N ratio of 2.6, whereas others have used less DNA. Our findings are in alignment with the recently reported result of Mignet et al who tested several percentages of DSPE-PEG2000 in lipoplexes and found that large aggregates occur in case of 1.25% and 2.5%, but not 5% PEG-lipid in the formula. Similarly, a size stabilizing effect exist when more than 4–5 mol% of a mono-alkyl- or cholesteryl-anchored PEG-lipid is incorporated into lipoplexes at neutral charge ratio. The biophysical basis of this difference may rely on the surface density of PEG-lipid that in less than 5% allow for a mushroom-structured PEG on the cationic liposome surface will lead to aggregated lipoplexes and brush like-structured PEG lead to more stable structures. It may be speculated that all PEG-lipid is not present in the lipoplex surface or even that some may form micelles, since the effect of polymer-based micelle formation has been reported when attempting to incorporate high mol% of DSPE-PEG2000 in liposome formulation. However, in this theoretical study it was predicted that 10% PEG2000-lipid would incorporate into liposome membrane spontaneously,
whereas longer PEG-chains might form micellar structures. The effect of inserting saturated lipid-PEG components in saturated membranes has been studied by spin-label electron spin resonance (ESR) spectroscopy. To our knowledge it has not been shown to what extent saturated PEG-lipids (DSPE-PEG2000) form micelles or pack into an unsaturated DOTAP/“bulky” lipid (cholesterol) membrane, but the aforementioned studies render it likely that although some PEG-lipid may be buried into the lamellar lipoplex structure, all PEG-lipid is retained in the lipoplex. Furthermore, the fact that the zeta potential of DOTAP/chol/DSPE-PEG2000 liposomes with 10% PEG-lipid is lower than 4% PEG-lipid (Figure 3, white columns), presumably due to the negative charge in the PE-head group, support that liposome composition is in accordance with the expected from the formulation.

When analyzing lipoplexes in vitro we found an inverse correlation between the amount of PEG-lipid in the lipoplex and reporter gene activity in both easy-to-transfect, adherent lung cancer H1299 cells and hard-to-transfect, suspension lung cancer NCI-H69 cells. Luciferase activity measurements showed that each stepwise increase in PEG-lipid percentage roughly reduced the luciferase activity by 10-fold, or three orders of magnitude. In accordance, the percentage of EGFP expressing cancer NCI-H69 cells. Luciferase activity measurements showed that that each stepwise increase in PEG-lipid percentage roughly reduced the luciferase activity by 10-fold, or three orders of magnitude. In accordance, the percentage of EGFP expressing cells was reduced one to two orders of magnitude to a level just above the detection limit. Using DOPE as the helper lipid several researchers have demonstrated a similar negative influence of increasing PEG-lipid in lipoplex formulation. Nicolazzi et al studied PEGylated lipoplexes with various charged peptide linkers in the PEG-lipid and confirmed the negative influence on transfection efficiency when analyzing lipoplexes with 5% PEG-lipid. Interestingly, a post insertion method for PEGylation of formed lipoplexes was used that enabled particles of much lower positive charge between 5 and 20 mV compared to 35 to 40 mV for PEGylated lipoplexes in this study, where PEG-lipid was incorporated from the beginning.

It could be speculated that lipoplex uptake mechanism and intracellular release could be altered by PEGylation, since it has been suggested that DOTAP/chol-based lipoplexes enter the cell by direct plasma membrane fusion or endocytosis-based upon electrostatic interactions. Using a NBD-cholesterol derivate we labeled the lipoplexes so that the lipid uptake could be monitored fluorometrically and it became evident that the kinetics of cellular uptake differs between PEGylated and non-PEGylated lipoplexes. Using a cell lysate microplate assay it was observed that within the first hour after addition, non-PEGylated lipoplexes enter the cells to a saturating limit. In contrast the uptake of PEGylated lipoplexes is gradually increasing over time and supposedly depends on an endocytotic mechanism that allow the accumulation of higher amounts of fluorescently labeled lipoplex – at least in the case of lipoplexes with 10% PEG-lipid where the fluorescent signal is twice that obtained from cells transfected with non-PEGylated lipoplexes.

This finding was further supported when radiolabeled lipoplexes were tested in cell culture and the label accumulating in cells after two days was measured (data not shown). Interestingly, fluorescence microscopy and flow cytometry show that with all four formulations virtually all cells contain the NBD-label after two days, hence it is indicated that the lost ability of PEGylated lipoplex to successfully transfect cells and allow the expression of reporter gene is due to defective intracellular processing and endocytic release of plasmid DNA. In support of this hypothesis we noted that lipoplexes made with plasmid and DODAC/DOPE/DSPE-PEG2000 showed that increasing mol% of PEG-lipid reduced the transfection after 24 hours. However, when analyzing cellular uptake of lipoplexes with radioactive lipids or nucleic acids it was concluded that PEG-induced inhibition of transfection did not correlate with a reduction in endocytosis. In addition, the uptake of oligodeoxynucleotides (ODN) complexed in DODAC/DOPE/PEG2000-ceramide (5%) lipoplexes was investigated and it was found that the stronger uptake correlated with longer ceramide PEG-anchors. Furthermore, using confocal microscopy an inverse correlation between ceramide lipid length and successful nuclear transfer of fluorescently labeled ODN was suggested, supporting the notion that DSPE-PEG2000 being C-18-anchored would inhibit endosomal escape similarly in our experiments and that unsuccessful transgene expression from PEGylated lipoplexes relate to that.

A profound change in sensitivity between non-PEGylated and PEGylated lipoplexes towards four endocytosis inhibitors thought to interfere with different uptake pathways was observed. Although the inhibitors may exert nonspecific effects, apparently, clathrin-coated endosomes are engaged in transfection using naked lipoplexes, since chlorpromazine reduced luciferase activity 8–16-fold in the lung cancer cell lines in our study and this was also found by others. The increase in luciferase activity from PEGylated lipoplexes when cells were exposed to chlorpromazine could be a competition effect of endocytic pathways – one being inhibited and thereby favoring another. Similarly, the sensitivity of A-0 lipoplexes towards chloroquine was also observed in both cell lines and in contrast chloroquine seems to have a stimulating effect on reporter activity from PEGylated lipoplexes. The latter is in alignment with the notion that PEGylated lipo-particles need to unload the DNA cargo before endosome fusion to lysosomes and degradation, however the inhibiting effect of
chloroquine on transfection with A-0-based lipoplexes was not easily interpretable. Several researchers have demonstrated that gene expression is increased in the presence of chloroquine when using 4% to 10% PEGylated small unilamellar liposomes as delivery vehicle involving passively targeted or receptor-targeted endocytosis. At least in NCI-H69 cells the sensitivity towards cytochalasin B was significant with all lipoplex formulations and hence a macropinocytosis-dependent uptake mechanism is suggested, although it cannot be formally ruled out that the disruption of endosomal trafficking by actin de-polymerization will influence the uptake through an unknown mechanism.

Difference in inhibitor sensitivity may depend on cell size and growth properties, NCI-H69 being small, growing in suspension, and adherent H1299 that are large and flattened out may require longer preincubation time, hence the cellular uptake of cationic lipoplexes and PEGylated lipoparticles may be cell type dependent in relation to endocytotic pathways at work.

Effect of PEGylation in vivo

The fate of the radiolabel allowed us to assess the systemic availability and retention in various organs. Surprisingly little radioactivity was detectable in blood isolated from the eye, only 0.01% to 0.1% of the injected dose was isolated in 100 μL blood 15 minutes after injection. A mouse weighing 30 g is estimated to contain approximately 3 g blood and hence if the entire dose was freely distributed in the blood and available we would expect 3.3%. One possibility is that due to the high positive charge (> +40 mV) and large aggregate size of the lipoplexes (all >300 nm) they do not make a full systemic passage, but are retained in the first primary organs after intravenous injection. In the heart and lungs all lipoplexes with 0% to 10% PEG-lipid are successful in transfection, but gradually decreasing corresponding to the activities measured in vitro. Comparing the reporter activity measured from lipoplexes made with A-0+ in Figure 1 and A-0 in Figure 7b, there is no difference (t-test, P value = 0.35), although the first was applied in three daily injections and the latter only once. We speculate that the duration of expression may not be long or that one dose is saturating in the reachable sites with this intravenous delivery method. Furthermore it is suggested that A-0 lipoplexes being 700 nm in size are as efficient in heart/lung transfection as A-0+ lipoplexes.

The positive charge of lipoplexes led to interaction with albumin and other serum proteins when exposed to serum or injected intravenously. Binding of lipoplexes to serum lipoproteins or complement factor C3 showed that it may have strong influence on particle size, DNA integrity, and transfection ability. When lipoplex size was assessed in the presence of serum proteins it was found that 5% PEG-lipid prevented a large increase in size over several hours that was observed in the case of non-PEGylated lipoplexes. The difference to the lipoplexes of the present study is that the N/P ratio is lower (1/5, less DNA complexed) and our particle’s surface charge is much higher presumably due to preincorporation of PEG-lipid that may not shield the charge as effectively as in case of postincorporation. Hence it may be amenable to utilize a lower N/P ratio, eg, 1/4 as reported, however that cause a decreased transfection in vivo.

Opsonization and uptake by phagocytic cells of the reticuloendothelial system (RES) present in blood was therefore expected in case of all four lipoplexes and indeed approximately 20% of the label resides in the spleen, since phagocytic blood cells accumulate later in the spleen as it was reported for liposome particles previously. Furthermore, luciferase activity found in the spleen when using A-0 lipoplexes could indicate successful transfection of RES cells accumulating in this organ (Figure 7b).

Analysis of lipoplexes with 0%, 2%, 4%, and 10% PEG-lipid allowed us to demonstrate that low PEG-lipid percentage (B-2, C-4) leads to severe lipoplex aggregation causing retention in lung/heart tissue similar to naked lipoplexes (A-0) that is not highly aggregated. Interestingly, with D-10 lipoplexes we observed a distribution in abdominal organs that suggests that heart/lung retention is overcome and although not being able to transfect cells in liver, kidney, and spleen lipoplexes are accumulating here. A similar distribution in inner organs was found when non-transplanted mice were used (data not shown) indicating that the inverse relation between lung/heart accumulation and 10% PEGylation is true also in noncancerous animals. Mice injected with lipoplexes maintained a normal behavior during the experiment, although we measured a significant weight loss of up to 10% in most of the animals. This could relate to some kind of pulmonary obstruction, however this was not visible in H&E staining of tissue sections, that were evaluated by a trained pathologist.

These observations support the notion that PEG shielding of lipoparticles increase systemic circulation, however due to the high positive surface charge only in the case of D10 lipoplexes was a small increase in blood availability measured. It has been previously reported that lipoplexes with 5% PEG-lipid could increase the blood availability marginally, however we found no increase in tumor accumulation. Neither of the lipoplex formulations convey delivery to tumor sites, hence our data confirm previous
reports that (non-PEGylated) DOTAP/chol lipoplexes\textsuperscript{2,15} or cationic DOPE-based lipoplexes including PEG-lipids\textsuperscript{25,45,48} do not mediate delivery to xenograft subcutaneous tumors to any useful extend.

**Conclusion**

We explored the potential of improving systemic stability and circulation of DOTAP/chol-based lipoplexes for in vivo cell transfection by including a PEG-lipid in the formulation. Although we observed a decrease in the retention in lung and heart tissues the systemic circulation was not considerably improved and the eminent properties of providing transfection and ectopic gene expression are lost upon increasing degrees of PEGylation, hereby rendering it unsuitable as a systemic delivery method for plasmid DNA-bound genetic medicine for extrathoracic sites.

**Acknowledgments**

The authors wish to extend their appreciation to Birgit Guldhulm for pathological evaluation of tissue section, Hanne Mørck Nielsen for access to Zetasizer, and Pia Pedersen for excellent technical assistance. This work was supported in part by a grant from the Danish Cancer Society and the Novo Nordisk Foundation. The authors report no conflicts of interest in this work.

**References**

1. Kang HC, Lee M, Bae YH. Polymeric gene carriers. *Crit Rev Eukaryot Gene Expr*. 2005;15:317–342.
2. Kawano T, Okuda T, Aoyagi H, Niidome T. Long circulation of intravenously administered plasmid DNA delivered with dendritic poly(L-lysine) in the blood flow. *J Control Release*. 2004;99:329–337.
3. Ewert KK, Ahmad A, Bouxein NF, Evans HM, Safinya CR. Non-viral gene delivery with cationic liposome-DNA complexes. *Methods Mol Biol*. 2008;483:159–175.
4. Safinya CR, Ewert K, Ahmad A, et al. Cationic liposome-DNA complexes: from liquid crystal science to gene delivery applications. *Philos Trans A Math Phys Eng Sci*. 2006;364:2573–2596.
5. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA: liposome complexes for increased systemic delivery and gene expression. *Nat Biotechnol*. 1997;15:647–652.
6. Ramesh R, Saeki T, Templeton NS, et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. *Mol Ther*. 2001;3:337–350.
7. Ramesh R. Nanoparticle-mediated gene delivery to the lung. *Methods Mol Biol*. 2008;433:301–331.
8. Sakurai F, Terada T, Maruyama M, et al. Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I: poly C in a murine lung metastasis model. *Cancer Gene Ther*. 2003;10:661–668.
9. Ito I, Ji L, Tanaka F, et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. *Cancer Gene Ther*. 2004;11:733–739.
10. Lu C, Sepulveda CA, Ji L, et al. Systemic therapy with tumor suppressor FUS1-nanoparticles for stage IV lung cancer. *American Association for Cancer Research Annual Meeting: Proceedings; 2007 Apr 14–18; Los Angeles, CA Philadelphia (PA): AACR*. 2007;Abstract nr LB-348. 2007.
11. Koltover I, Salditt T, Safinya CR. Phase diagram, stability, and overcharging of lamellar cationic lipid-DNA self-assembled complexes. *Biophys J*. 1999;77(2):915–924.
12. Templeton NS. Nonviral delivery for genotoxic therapy of cancer. *World J Surg*. 2009;33:685–697.
13. Tam P, Monck M, Lee D, et al. Stabilized plasmid-lipid particles for systemic gene therapy. *Gene Ther*. 2000;7:1867–1874.
14. Christensen CL, Zandi R, Gjetting T, Cramer F, Poulsen HS. Specifically targeted gene therapy for small-cell lung cancer. *Expert Rev Anticancer Ther*. 2009;9:437–452.
15. Pedersen N, Mortensen S, Sorensen SB, et al. Transcriptional gene expression profiling of small cell lung cancer cells. *Cancer Res*. 2003;63:1943–1953.
16. Christensen CL, Gjetting T, Poulsen TT, Cramer F, Roth JA, Poulsen HS. Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer specific cytotoxicity and tumor growth delay. *Clin Cancer Res*. 2010;16:2308–2319.
17. Chua YJ, Steer C, Yip D. Recent advances in management of small-cell lung cancer. *Cancer Treat Rev*. 2004;30:521–543.
18. Charrois GJ, Allen TM. Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. *Biochim Biophys Acta*. 2003;1609:102–108.
19. Santel A, Aleku M, Keil O, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. *Gene Ther*. 2006;13:1222–1234.
20. Woodle MC, Lasic DD. Sterically stabilized liposomes. *Biochim Biophys Acta*. 1992;1113:171–199.
21. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. *Science*. 2004;303:1818–1822.
22. Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: an overview. *Adv Drug Deliv Rev*. 2009;61:1177–1188.
23. Kenworthy AK, Hristova K, Needham D, McIntosh TJ. Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). *Biophys J*. 1995;68:1921–1936.
24. Tiros O, Barenholz Y, Katchanderl J, Priev A. Hydration of polyethylene glycol-grafted liposomes. *Biophys J*. 1998;74:1371–1379.
25. Nicolazzi C, Mignet N, de la FN, et al. Anionic polyetyleneglycol lipids added to cationic lipoplexes increase their plasmatic circulation time. *J Control Release*. 2003;88:429–443.
26. Mignet N, Cadet M, Bessodes M, Scherman D. Incorporation of poly(ethylene glycol) lipid into lipoplexes: On-line incorporation assessment and pharmacokinetics advantages. *Liposome technology*. Third ed. 2007;273–292.
27. Heyes J, Palmer L, Chan K, Giesbrecht C, Jeffs L, Maclachlan I. Lipid encapsulation enables the effective systemic delivery of polyplex plasmid DNA. *Mol Ther*. 2007;15:713–720.
28. Skjorringe T, Gjetting T, Jensen TG. A modified protocol for efficient DNA encapsulation into pegylated immunoliposomes (PILs). *J Control Release*. 2009;139:140–145.
29. Schnitzer JE, Oh P, Pinney E, Allard J. Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. *J Cell Biol*. 1999;127:1217–1232.
30. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. *Biochem J*. 2004;377:159–169.
31. Theodoropoulos PA, Gravanis A, Tsapara A, et al. Cytochalasin B may shorten actin filaments by a mechanism independent of barbed end capping. *Biochem Pharmacol*. 1994;47:1875–1881.
32. Poulsen TT, Pedersen N, Juel H, Poulsen HS. A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells. *Cancer Gene Ther*. 2008;15:563–575.

33. Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. *Biochim Biophys Acta*. 2004;1663:167–177.

34. Bally MM, Mayer LD, Hope MJ, Naya R. Pharmacodynamics of liposomal drug carriers: methodological considerations. In: Gregoraciad G, editor. Liposome technology. Second ed. London, UK: CRC Press; 1993:27–39.

35. Deng WG, Wu G, Ueda K, Xu K, Roth JA, Ji L. Enhancement of the cellular internalization and transfection efficiency of lipid-DNA particles. *Biochem Soc Trans*. 2005;33:336–347.

36. Luo D, Saltzman WM. Synthetic DNA delivery systems. *Nat Biotechnol*. 2000;18:33–37.

37. Monck MA, Mori A, Lee D, et al. Stabilized plasmid-lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection. *J Drug Target*. 2000;7:439–452.

38. Song LY, Akhong QE, Rong Q, et al. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. *Biochim Biophys Acta*. 2002;1558:1–13.

39. Masson C, Garinot M, Mignet N, et al. pH-sensitive PEG lipids containing orthoester linkers: new potential tools for nonviral gene delivery. *J Cont Rel*. 2004;99:423–434.

40. Zhang Y, Bradshaw-Pierce EL, Delille A, Gustafson DL, Anchordoquy TJ. In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: Effects on biodistribution and tumor accumulation. *J Pharm Sci*. 2008;97:237–250.

41. Faneca H, Simoes S, de Lima MCP. Association of albumin or hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells. *Cancer Gene Ther*. 2008;15:29–39.

42. Ramesh R, Ito I, Saito Y, et al. Local and systemic inhibition of lung tumor growth after nanoparticle-mediated md-a-7/IL-24 gene delivery. *DNA Cell Biol*. 2004;23:850–857.

43. Llerner D, Weibel JM, Heissler D, Zuber G, Duportail G, Mely Y. Dependence of the cellular internalization and transfection efficiency on the structure and physicochemical properties of cationic detergent/DNA/liposomes. *J Gene Med*. 2004;6:415–428.

44. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. *Proc Natl Acad Sci U S A*. 1987;84:7413–7417.

45. Nghiem P, Voelkel N, Rong Q, et al. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. *Biochim Biophys Acta*. 2004;1663:143–157.

46. Smyth TN. Cationic liposomes as in vivo delivery vehicles. *Curr Med Chem*. 2003;10:1279–1287.

47. Song LY, Akhong QE, Rong Q, et al. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. *Biochim Biophys Acta*. 2002;1558:1–13.

48. Masson C, Garinot M, Mignet N, et al. pH-sensitive PEG lipids containing orthoester linkers: new potential tools for nonviral gene delivery. *J Cont Rel*. 2004;99:423–434.

49. Zhang Y, Bradshaw-Pierce EL, Delille A, Gustafson DL, Anchordoquy TJ. In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: Effects on biodistribution and tumor accumulation. *J Pharm Sci*. 2008;97:237–250.

50. Vithaya D, Bartucci R, Belsito S, Marsh D, Sportelli L. Lipid membrane expansion and micelle formation by polymer-grafted lipids: Scaling with polymer length studied by spin-label electron spin resonance. *Biophys J*. 2001;80:1372–1383.

51. Chenevier P, Veyret B, Roux D, Henry-Toulme N. Interaction of cationic liposomes and their DNA complexes with monocytic leukemia cells. *Biochim Biophys Acta*. 1999;1418:71–84.

52. Monck MA, Mori A, Lee D, et al. Stabilized plasmid-lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection. *J Drug Target*. 2000;7:439–452.

53. Ivanov AI. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? *Methods Mol Biol*. 2008;440:15–33.

54. Rejman J, Dragonzi A, Conese M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. *Mol Ther*. 2005;12:468–474.

55. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. *Nat Med*. 2004;10:310–315.

56. Cornelis S, Vandenbranden M, Ruyschaert JM, Elouahabi A. Role of intracellular cationic liposome-DNA complex dissociation in transfection mediated by cationic lipids. *DNA Cell Biol*. 2002;21:91–97.

57. John Working Group on Refinement. Removal of blood from laboratory mammals and birds. First report of the BVA/FRAME/RSPCA/UFAW Joint Working Group on Refinement. *Lab Anim*. 1993;27:1–22.

58. Zhang Y, Anchordoquy TJ. The role of lipid charge density in the serum stability of cationic lipid/DNA complexes. *Biochim Biophys Acta*. 2004;1663:143–157.

59. Faneca H, Simoes S, de Lima MCP. Association of albumin or protamine to lipoplexes: enhancement of transfection and resistance to serum. *J Gene Med*. 2004;6:681–692.

60. Tandia BM, Lonez C, Vandenbergen M, Ruyschaert JM, Elouahabi A. Lipid mixing between lipoplexes and plasma lipoproteins is a major barrier for intravenous transfection mediated by cationic lipids. *J Biol Chem*. 2005;280:12255–12261.

61. Mclean JW, Fox EA, Baluk P, et al. Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. *Am J Phys-Heart Circu Phys*. 1997;42:387–404.

62. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin formulations in murine breast cancer. *Cancer Res*. 1994;54:987–992.